Ashvattha Therapeutics, Inc
Ashvattha Therapeutics, Inc., based in Redwood City, CA, is a clinical-stage biopharmaceutical company dedicated to developing innovative precision nanomedicines aimed at addressing unmet medical needs in ophthalmology, neurology, and inflammatory diseases. Utilizing their proprietary hydroxyl dendrimer (HD) technology, the company focuses on creating targeted therapeutics that selectively engage inflamed tissues, thereby enhancing treatment precision.
The company's lead therapeutic candidate, Migaldendranib, is designed to cross the blood-retinal barrier and specifically target activated microglia, macrophages, and retinal pigment epithelial cells in the eye. Ashvattha Therapeutics is committed to redefining standards of care through its advanced nanomedicine approach, which seeks to empower precision medicine across various medical fields.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.